The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes-Reference-Cited by-同舟云学术

The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes

Published:2024-08-01 Issue:2 Volume:327 Page:E145-E154
ISSN:0193-1849
Container-title:American Journal of Physiology-Endocrinology and Metabolism
language:en
Short-container-title:American Journal of Physiology-Endocrinology and Metabolism

Author:

Larsen Anna Thorsø¹^ORCID,Mohamed Khaled Elhady¹,Melander Simone Anna¹^ORCID,Karsdal Morten Asser¹²,Henriksen Kim¹²³

Affiliation:

1. Nordic Bioscience, Herlev, Denmark

2. KeyBioscience AG, Stans, Switzerland

3. Department of Science and Environment, Roskilde University, Roskilde, Denmark

Abstract

These studies describe the benefit of combining dual amylin and calcitonin receptor agonists (DACRA) with semaglutide for long-term treatment of obesity and type 2 diabetes. Combination treatment induced sustained weight loss and improved glucose control. A DACRA-driven reduction in a serological biomarker of cardiac fibrosis indicated a reduced risk of complications. These results highlight DACRAs as a promising candidate for combination treatment of obesity and type 2 diabetes and related long-term complications.

Funder

Innovation Fund Denmark

European Union's horizon 2020 research and innovation program under the Marie Sklodowske-Curie

Publisher

American Physiological Society

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpendo.00092.2024

Reference61 articles.

1. Obesity: global epidemiology and pathogenesis

2. Obesity in adults: a clinical practice guideline

3. Benefits of weight loss of 10% or more in patients with overweight or obesity: A review

4. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

5. Weight Change–Adjusted Effects of Gastric Bypass Surgery on Glucose Metabolism: 2- and 10-Year Results From the Swedish Obese Subjects (SOS) Study